drugset
drugset / Trial / NCT01264692

Essential Hypertension

NCT01264692 ↗

Phase 2 Completed 196 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.

Timeline

Start
2011-02
Primary completion
2012-01
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ACT-280778 Small molecule 10 mg Oral
Subject Amlodipine Other / unclassified 10 mg —

Indications

essential hypertension